Compare Bristol-Myers Squibb Co (BMY) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Omnicom Group Inc. — how do they compare? Bristol-Myers Squibb Co trades at $58.54 (market cap $116.30B), while Omnicom Group Inc. trades at $81.79 (market cap $23.01B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.1× Omnicom Group Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | OMC | |
|---|---|---|
Market Cap | $116.30B | $23.01B |
Sector | Health | Media |
52-Week High | $62.37 | $85.80 |
52-Week Low | $42.60 | $67.27 |
Enterprise Value | $152.24B | $30.24B |
Dividend Yield | 4.42% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Omnicom Group (OMC) trades at $82.55, up 0.76% today, with a bullish technical signal from moving averages. The stock shows mixed earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results due July 28, 2026. Revenue grew to $17.27B in 2025, though net income was negative, and cash flow improved significantly. Recent news highlights partnerships with IBM, Netflix, and NBCUniversal, enhancing its media and advertising solutions.
Outlook is cautiously optimistic with a consensus price target of $105.75, implying 28% upside, but risks include intense competition and thin profit margins. The stock offers value with a P/E of 12.16 and a dividend, yet investors should monitor earnings sustainability and debt levels amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
